A Hopkins researcher is examining whether a 100-year-old method to take antibodies from patients who recover from Covid-19, and transferring this immunity through a serum, may prove effective to those at risk of the infection. This method fell out of favor, after being used for measles and polio, because of vaccines and antibiotics. This serum method is not without risk, but could be developed in weeks rather than months for a Covid-19 vaccine.
hub.jhu.edu/2020/03/03/casa...
As noted on this Health Unlocked forum, the use of antimalarials may be an effective use for Covid19, but they are clinically unproven for COVID-19. Other important info is that these drugs are used daily by those with juvenile idiopathic arthritis, lupus and rheumatoid arthritis to prevent severe organ and tissue problems and the drugs may be in short supply for those who now use them for their diseases if diverted to Covid-19. Patients who try to use them for lupus, etc., have to be able to withstand the side effects or not experience side effects. According to a neighbor in health care, that I spoke with yesterday, these drugs can have "really nasty side effects."
Here is a primer on current use of these drugs in autoimmune diseases.
hopkinslupus.org/lupus-trea...
Interestingly, I just read that Bayer and Teva may be donating millions of tabs of anti-malarials to U.S. However, the FDA commissioner is cautioning that we need to have "a large, pragmatic clinical trial" before using these drugs for Covid-19.